Agepha Pharma Fz LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$208Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
617clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Paul Ridker | Boston, MA | Cardiovascular Disease | $83,455.96 |
| Payal Kohli | Aurora, CO | Cardiovascular Disease | $15,021.66 |
| Andrew Freeman | Denver, CO | Cardiovascular Disease | $14,238.63 |
| Robert Quigley | Philadelphia, PA | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $9,500.00 |
| Amin Sabet | Fresno, CA | Cardiovascular Disease | $9,136.36 |
| Jimmy Kerrigan | Nashville, TN | Interventional Cardiology | $9,097.90 |
| Matthew Budoff | Torrance, CA | Cardiovascular Disease | $6,524.34 |
| Philip Nimoityn | Philadelphia, PA | Cardiovascular Disease | $6,403.53 |
| Henry Siu | New York, NY | Interventional Cardiology | $5,367.79 |
| Henock Saint Jacques | New York, NY | Cardiovascular Disease | $4,794.13 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.